Can Adding Radium-223 to RT Boost Prostate Cancer Outcomes?
TOPLINE: Adding radium-223 dichloride (Ra223) to metastasis-directed stereotactic ablative radiotherapy (SABR) did not improve progression-free survival compared with SABR alone in men with bone-only oligometastatic castration-sensitive prostate cancer, according to a phase 2 trial. However, the authors identified two potential prognostic biomarkers — high-risk DNA mutations and T-cell receptor repertoire diversity — to predict progression-free … Read more